Related Experiment Video
Updated: Jun 3, 2026
12:03
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Aptamer-targeted RNAi for HIV-1 therapy.
1Division of Molecular and Cellular Biology, Irell and Manella Graduate School of Biological Sciences, Beckman Research Institute of City of Hope, City of Hope, Duarte, CA, USA.
Methods in Molecular Biology (Clifton, N.J.)
|March 25, 2011
Summary
Novel aptamer-siRNA systems deliver RNA interference (RNAi) therapeutics to inhibit HIV-1. These systems target the virus
Area of Science:
- Biotechnology
- Molecular Biology
- Immunology
Background:
- RNA interference (RNAi) is a specific gene-silencing mechanism with therapeutic potential.
- Developing effective RNAi therapeutics requires efficient and targeted delivery systems.
- Human Immunodeficiency Virus type 1 (HIV-1) remains a significant global health challenge.
Purpose of the Study:
- To develop novel cell type-specific delivery systems for RNAi-based HIV-1 therapy.
- To create dual-function molecules combining aptamers and small interfering RNAs (siRNAs) with anti-HIV activity.
Main Methods:
- Designed chimeric aptamer-siRNA molecules targeting the HIV-1 envelope glycoprotein (gp120).
- Utilized anti-gp120 aptamers for cell-specific binding and internalization of siRNA payloads.
- Employed Dicer-substrate siRNAs designed for functional processing and gene silencing.
Main Results:
- Demonstrated potent anti-HIV activity of both aptamer and siRNA components in the chimeric molecules.
- Showcased successful binding and internalization of aptamer-siRNA constructs into HIV-1 infected cells.
- Confirmed specific inhibition of HIV-1 replication and infectivity in CEM T-cells and primary blood mononuclear cells via Dicer processing of siRNA.
Conclusions:
- Developed novel aptamer-targeted RNAi therapeutics for combating HIV-1.
- Validated the use of anti-gp120 aptamers as effective delivery vehicles for Dicer-substrate siRNAs.
- Established a promising strategy for targeted gene silencing in HIV-1 therapy.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...